FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 140 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... August 15, 2019 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 New Blood Test Can Screen For Over 50 Cancers June 7, 2021 No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in... June 15, 2022 Load more HOT NEWS Get to Know CaringBridge These Triplets Were Tired Of Being Mistaken For Each Other. Their... Breaking the silence: when cancer steals your voice FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer
